
    
      Lung adenocarcinoma is the most common NSCLC,most patient were diagnosed to advanced stage.
      Maintenance treatment is the continuation of treatment after first-line treatment and before
      the disease progresses. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to
      the therapy of these patients. We designed the study to explore the possibility of apatinib
      for maintenance.
    
  